Study of new treatment for microscopic colitis in remission
Part of Digestive system clinical trials.
This study tests whether a new medication (SAR444336) can help adults with microscopic colitis stay in remission longer. It may be an option if you are already taking budesonide and have had flares in the past 8 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of microscopic colitis (any type).
- You are currently taking budesonide to control your colitis.
- You have had at least one colitis flare in the last 8 months that needed treatment with budesonide.
- Your colitis symptoms have been under control (clinical remission) for at least 2 weeks before the study starts.
- You do not have other inflammatory bowel diseases like Crohn's or ulcerative colitis, or a history of certain serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two forms of the same medicine, budesonide, to see which one works better and is safer for bringing microscopic colitis symptoms under control. If you have active watery/loose diarrhea and confirmed microscopic colitis, you may be offered one of these treatments to induce remission.
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
This trial tests a new medicine called SAR441566 for people with moderate-to-severe ulcerative colitis (UC). It may help reduce symptoms like bleeding and diarrhea if other treatments haven't worked well enough.
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Hear when a new Microscopic Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.